Fusion Pharmaceuticals Inc. Proceeds from Issuance Initial Public Offering
Fusion Pharmaceuticals Inc. reported Proceeds from Issuance Initial Public Offering of $197.63 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2022-03-17
- Fusion Pharmaceuticals Inc. proceeds from issuance initial public offering for the quarter ending 2020-12-31 was $0.00.
- Fusion Pharmaceuticals Inc. proceeds from issuance initial public offering for the quarter ending 2020-09-30 was $0.00.
- Fusion Pharmaceuticals Inc. proceeds from issuance initial public offering for fiscal 2020 was $197.63M.
| Period end | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 6 month | Proceeds from Issuance Initial Public Offering 9 month | Proceeds from Issuance Initial Public Offering 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $197.63M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $197.63M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $197.63M 10-Q · filed 2021-08-10 |